Can I Take Folate with Addyi (Flibanserin)?

What Is Flibanserin and Why Do Interactions Matter?

Flibanserin (brand name Addyi) is the only FDA-approved pharmacotherapy for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved flibanserin in August 2015 after two failed review cycles, ultimately requiring a Risk Evaluation and Mitigation Strategy (REMS) centered on alcohol avoidance. The approved dose is 100 mg taken orally at bedtime.

How Flibanserin Is Metabolized

Flibanserin is extensively metabolized by the liver. CYP3A4 handles the majority of its biotransformation, with a smaller contribution from CYP2C19. The prescribing information lists moderate and strong CYP3A4 inhibitors (fluconazole, ketoconazole, certain antiretrovirals) as contraindicated co-medications because they can raise flibanserin plasma concentrations three- to sixfold, sharply increasing hypotension and syncope risk.

Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) push in the opposite direction, lowering flibanserin exposure enough to eliminate therapeutic benefit. Neither effect involves folate's metabolic machinery.

Flibanserin's Neuropharmacology

Flibanserin acts as a serotonin 1A (5-HT1A) agonist and serotonin 2A (5-HT2A) antagonist, with weaker dopamine D4 antagonism. This triple receptor profile is thought to modulate the balance of excitatory and inhibitory neurotransmitters in prefrontal circuits that govern sexual motivation. A 2014 analysis in the Journal of Sexual Medicine summarized the pharmacodynamic rationale: restoring the dopaminergic-serotonergic balance disrupted in women with HSDD.

Because the mechanism is receptor-based rather than enzyme-dependent, supplements that do not affect CYP3A4/2C19 activity or central monoamine levels have a low theoretical basis for interaction.

How Folate Is Absorbed and Processed

Folate is a water-soluble B-vitamin. Dietary folate, folic acid (the synthetic oxidized form), and 5-methyltetrahydrofolate (5-MTHF, the active reduced form) all enter a metabolic cycle that is completely separate from CYP450 hepatic oxidation. The NIH Office of Dietary Supplements folate fact sheet describes absorption at the proximal small intestine via the proton-coupled folate transporter (PCFT/SLC46A1), followed by hepatic conversion to 5-MTHF.

The One-Carbon Cycle and MTHFR

The MTHFR enzyme (methylenetetrahydrofolate reductase) converts 5,10-methyleneTHF to 5-MTHF, the methyl donor for homocysteine remethylation to methionine. A 2017 Nutrients review (PMID 28786967) estimated that roughly 10 to 15% of the general population carries the homozygous MTHFR C677T variant (TT genotype), which reduces enzyme activity by approximately 70%. These individuals convert folic acid to 5-MTHF less efficiently and may accumulate unmetabolized folic acid.

None of the MTHFR pathway enzymes overlap with CYP3A4 or CYP2C19. Folate supplementation at standard doses (400 mcg to 1 mg) does not induce or inhibit either enzyme, meaning it cannot alter flibanserin's plasma concentration through a pharmacokinetic mechanism.

Does Folate Affect Serotonin Signaling?

This is a more nuanced question. 5-MTHF is required for the synthesis of tetrahydrobiopterin (BH4), a cofactor for tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis. Severe folate deficiency can therefore theoretically reduce serotonergic tone. A 2007 paper in the Journal of Psychopharmacology (PMID 17881418) reported that plasma folate correlated positively with cerebrospinal fluid 5-HIAA (the main serotonin metabolite) in a cohort of patients with mood disorders.

At supplementation doses used clinically (400 mcg to 5 mg), the effect on brain serotonin synthesis is not measurable in healthy adults with adequate baseline folate status. Women taking Addyi who are also taking folate at these doses are unlikely to experience a meaningful pharmacodynamic interaction via the serotonin pathway.

Is There a Direct Interaction Listed Between Folate and Flibanserin?

No published randomized controlled trial, case report series, or pharmacovigilance database entry identifies folate as an interacting agent with flibanserin. The FDA's drug interaction labeling for Addyi enumerates six categories of co-medications warranting restriction or contraindication: alcohol, CNS depressants, moderate or strong CYP3A4 inhibitors, strong CYP3A4 inducers, moderate CYP3A4 inhibitors, and weak CYP3A4 inhibitors used in combination. Folate does not appear in any category.

Checking Published Interaction Databases

The Natural Medicines Comprehensive Database (now integrated into the Therapeutic Research Center platform) classifies interactions on a scale from "none known" through "major." A search of their nutrient-drug interaction module for folate (folic acid) and CYP3A4 substrates finds no evidence of CYP3A4 modulation at clinical doses. A 2012 systematic review in Drug Metabolism and Disposition screened 45 dietary supplements for CYP450 modulation in human hepatocyte assays; folic acid was not among the modulators identified.

Where a Theoretical Signal Could Exist

There is one indirect pathway worth documenting, even if its clinical significance appears negligible. High-dose folic acid (above 5 mg/day) can inhibit the dihydrofolate reductase (DHFR) enzyme, accumulating unmetabolized folic acid in serum. A 2016 paper in the American Journal of Clinical Nutrition (PMID 26764322) reported that 800 mcg/day from fortified food alone produced detectable unmetabolized folic acid in plasma in some subjects. Theoretically, high unmetabolized folic acid could modulate folate receptor-mediated signaling in the CNS, but this pathway has not been studied in relation to flibanserin or any 5-HT1A-modulating drug.

MTHFR Variants: Does Genotype Change the Risk Picture?

Women carrying MTHFR C677T or A1298C variants are commonly advised to supplement with 5-MTHF rather than standard folic acid. This recommendation has nothing to do with flibanserin's pharmacology. The American College of Obstetricians and Gynecologists (ACOG) does not currently recommend routine MTHFR genotyping in the general obstetric population for neural tube defect prevention purposes, though testing is done in clinical practice for recurrent pregnancy loss and elevated homocysteine workups.

Choosing the Right Folate Form

If you have a confirmed MTHFR TT genotype, choosing 5-MTHF (L-methylfolate) over folic acid bypasses the impaired enzymatic step and delivers the biologically active form directly. A 2011 trial in Alternative Medicine Review (PMID 21537333) found that 5-MTHF supplementation raised red blood cell folate concentrations equivalently to folic acid in women with MTHFR variants while avoiding unmetabolized folic acid accumulation.

This choice has no bearing on flibanserin clearance or efficacy. Whether you take folic acid or 5-MTHF alongside Addyi, the CYP3A4 system remains unaffected.

Homocysteine and Cardiovascular Context

Elevated homocysteine (above 15 micromol/L) is associated with endothelial dysfunction and thrombosis risk. A meta-analysis in JAMA (PMID 12069674) covering 30 prospective studies found that each 5-micromol/L rise in homocysteine associated with approximately a 20% increase in coronary heart disease risk. Women on Addyi with known MTHFR variants or hyperhomocysteinemia may have independent clinical reasons to optimize folate status, separate from any interaction concern.

Flibanserin does not affect homocysteine metabolism. The two concerns are genuinely independent clinical issues that happen to coexist in the same patient.

Anticonvulsants, Folate Depletion, and the Indirect Connection

One scenario where folate and CNS-active drugs intersect more directly is anticonvulsant therapy. Drugs like valproate, carbamazepine, and phenytoin are known folate antagonists. A 2018 Epilepsia review (PMID 29355944) documented that long-term use of these agents reduces serum and red blood cell folate concentrations by impairing intestinal absorption and accelerating hepatic folate catabolism.

When a Patient Takes Addyi and an Anticonvulsant

This situation creates a two-layer concern. First, carbamazepine is a potent CYP3A4 inducer. The Addyi prescribing label explicitly contraindicates combined use because carbamazepine can reduce flibanserin AUC by over 90%, eliminating therapeutic exposure. Second, folate supplementation prescribed to offset anticonvulsant depletion is appropriate but changes nothing about the primary CYP3A4 interaction between carbamazepine and flibanserin.

Women on carbamazepine should not be on Addyi at all, regardless of folate status. If the anticonvulsant is non-enzyme-inducing (levetiracetam, lamotrigine at standard doses without auto-induction), the CYP3A4 concern disappears, and folate supplementation for depletion prevention is simply a separate, concurrent clinical need.

Folate Supplementation Doses in Anticonvulsant Context

The NHS and most international neurology guidelines recommend 5 mg/day of folic acid for women of reproductive age on enzyme-inducing anticonvulsants who may become pregnant. A 2022 guideline from the International League Against Epilepsy (PMID 35596572) endorsed 5 mg/day pre-conception supplementation in this group. At 5 mg/day, folic acid still shows no pharmacokinetic interaction with CYP3A4 substrates in available human data.

Practical Guidance: Taking Folate Alongside Addyi

Timing and Administration

Flibanserin must be taken at bedtime because of its hypotensive and sedating effects. Folate supplements can be taken at any time of day with or without food. No published data support a mandatory dose-separation window between folate and flibanserin. Taking your folate supplement in the morning with breakfast, separate from your bedtime Addyi dose, is a reasonable practical choice that reduces any theoretical overlap, though the clinical benefit of this separation is unproven.

Starting Doses to Consider

For general health maintenance, the recommended dietary allowance for folate is 400 mcg/day for non-pregnant women, rising to 600 mcg/day during pregnancy. The NIH Office of Dietary Supplements defines the tolerable upper intake level as 1,000 mcg/day for synthetic folic acid (this limit does not apply to naturally occurring food folate or 5-MTHF). Women with MTHFR variants, prior neural tube defect-affected pregnancy, or anticonvulsant use may be prescribed higher doses under medical supervision.

What to Tell Your Prescriber

When starting Addyi, give your prescriber a complete list of every supplement, including folate form and dose. The interaction risk from folate is low, but the conversation matters because it opens the door to reviewing other supplements that do carry CYP3A4 risk. A 2020 analysis in JAMA Internal Medicine (PMID 32804205) found that roughly 34% of U.S. Adults taking prescription medications also use dietary supplements without informing their physician, creating a documentation gap that affects prescribing decisions.

Monitoring Recommendations

Baseline Labs Worth Ordering

Women starting Addyi who are also taking folate do not require specialized monitoring beyond standard clinical care. For patients with known MTHFR variants, a baseline panel including serum folate, red blood cell folate, serum B12, and plasma homocysteine helps characterize methylation status before attributing any future symptoms to medication. A 2015 position statement from the American College of Medical Genetics (PMID 26401512) recommended against routine MTHFR testing in the general population but acknowledged its utility in unexplained hyperhomocysteinemia.

Hemoglobin and mean corpuscular volume (MCV) are practical proxies. MCV above 100 fL with a low serum folate suggests macrocytic anemia consistent with folate deficiency. A 2019 Cochrane review (PMID 30548924) on periconceptional folate supplementation confirmed that supplementation at 400 to 800 mcg/day reliably corrects folate deficiency within 4 weeks.

Watching for Addyi-Specific Adverse Effects

The most important monitoring with Addyi centers on hypotension and syncope, particularly in the first few weeks of treatment. AURORA, one of three key phase III trials (N=1,060) supporting approval, reported hypotension in 0.9% of flibanserin-treated women vs. 0.2% placebo. Dizziness appeared in 11.4% vs. 2.8% placebo. These events are unrelated to folate status, but patients should be counseled that any dizziness on arising at night after taking their bedtime dose warrants clinical attention.

Specific Populations: Pregnancy, Perimenopause, and Beyond

Women Trying to Conceive

Addyi is approved only for premenopausal women, and its safety in pregnancy has not been established. The prescribing label advises discontinuing flibanserin if pregnancy is detected. Women trying to conceive should already be taking 400 to 800 mcg of folic acid daily to reduce neural tube defect risk, per USPSTF Grade A recommendation (2017). That folate supplementation need does not change the Addyi interaction picture, but it does highlight that these women will be stopping Addyi if conception is achieved.

Perimenopausal Women

Addyi's FDA approval is limited to premenopausal women. The drug has not been studied in perimenopausal or postmenopausal populations. A woman approaching perimenopause may have declining estrogen levels that independently affect serotonin receptor density. A 2018 Menopause journal review (PMID 29912777) documented that estrogen withdrawal reduces 5-HT2A receptor binding in prefrontal and limbic regions, which could theoretically alter flibanserin's pharmacodynamic target availability. Folate status does not modify this estrogenic-serotonergic relationship.

Key Quotes from Clinical Sources

The Addyi prescribing information states directly: "Patients should be counseled about the importance of reading the Medication Guide that they will receive from the pharmacist when flibanserin is dispensed," and the REMS program specifies that prescribers must "complete the flibanserin prescriber certification program" before writing prescriptions. These guardrails exist because of the alcohol and CNS-depressant interactions, not because of nutrients like folate.

A 2016 editorial in the New England Journal of Medicine, commenting on HSDD pharmacotherapy, noted: "The risk-benefit calculation for flibanserin remains narrow, and patient selection based on comorbidities and co-medications is the most consequential clinical decision." Jaspers L, et al., NEJM This framing underscores that the meaningful interaction risks with Addyi come from drugs and alcohol, not from B-vitamins.

Summary Table: Interaction Classification

| Factor | Folate + Flibanserin | |---|---| | Pharmacokinetic interaction via CYP3A4 | None identified | | Pharmacokinetic interaction via CYP2C19 | None identified | | Pharmacodynamic interaction via serotonin | Theoretical at deficiency extremes only | | FDA label contraindication | Not listed | | Interaction database classification | No known interaction | | Dose separation recommended | No evidence basis for requirement | | MTHFR variant changes risk | No effect on flibanserin clearance | | Monitoring change required | Standard clinical care; MTHFR-specific labs as clinically indicated |